Design considerations for tumour-targeted nanoparticles
Source abstract
Abstract
Inorganic/organic hybrid nanoparticles are potentially useful in biomedicine, but to avoid non-specific background fluorescence and long-term toxicity, they need to be cleared from the body within a reasonable timescale. Previously, we have shown that rigid spherical nanoparticles such as quantum dots can be cleared by the kidneys if they have a hydrodynamic diameter of approximately 5.5 nm and a zwitterionic surface charge. Here, we show that quantum dots functionalized with high-affinity small-molecule ligands that target tumours can also be cleared by the kidneys if their hydrodynamic diameter is less than this value, which sets an upper limit of 5-10 ligands per quantum dot for renal clearance. Animal models of prostate cancer and melanoma show receptor-specific imaging and renal clearance within 4 h post-injection. This study suggests a set of design rules for the clinical translation of targeted nanoparticles that can be eliminated through the kidneys.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Quantum Dots Synthesis And Properties · Gold and Silver Nanoparticles Synthesis and Applications · Nanocluster Synthesis and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (30)
Show source-provided references
1. Frangioni, J. V. New technologies for human cancer imaging. J. Clin. Oncol. 26, 4012–4021 (2008).10.1200/JCO.2007.14.3065 ↗
2. Choi, H. S. et al. Renal clearance of quantum dots. Nature Biotechnol. 25, 1165–1170 (2007).10.1038/nbt1340 ↗
3. Alivisatos, P. The use of nanocrystals in biological detection. Nature Biotechnol. 22, 47–52 (2004).10.1038/nbt927 ↗
4. Gao, X., Cui, Y., Levenson, R. M., Chung, L. W. & Nie, S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nature Biotechnol. 22, 969–976 (2004).10.1038/nbt994 ↗
5. Michalet, X. et al. Quantum dots for live cells, in vivo imaging and diagnostics. Science 307, 538–544 (2005).10.1126/science.1104274 ↗
6. Medintz, I. L., Uyeda, H. T., Goldman, E. R. & Mattoussi, H. Quantum dot bioconjugates for imaging, labelling and sensing. Nature Mater. 4, 435–446 (2005).10.1038/nmat1390 ↗
7. Harisinghani, M. G. et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348, 2491–2499 (2003).10.1056/NEJMoa022749 ↗
8. Frangioni, J. V. Translating in vivo diagnostics into clinical reality. Nature Biotechnol. 24, 909–913 (2006).10.1038/nbt0806-909 ↗
9. Colvin, V. The potential environmental impact of engineered nanomaterials. Nature Biotechnol. 21, 1166–1170 (2003).10.1038/nbt875 ↗
10. Duncan, R. Polymer conjugates as anticancer nanomedicines. Nature Rev. Cancer 6, 688–701 (2006).10.1038/nrc1958 ↗
11. Weissleder, R., Kelly, K., Sun, E. Y., Shtatland, T. & Josephson, L. Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nature Biotechnol. 23, 1418–1423 (2005).10.1038/nbt1159 ↗
12. Ballou, B. et al. Sentinel lymph node imaging using quantum dots in mouse tumor models. Bioconjug. Chem. 18, 389–396 (2007).10.1021/bc060261j ↗
13. Qian, X. et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nature Biotechnol. 26, 83–90 (2008).10.1038/nbt1377 ↗
14. Peer, D. et al. Nanocarriers: emerging platforms for cancer therapy. Nature Nanotech. 2, 751–760 (2007).10.1038/nnano.2007.387 ↗
15. Hamad, I., Hunter, A. C., Szebeni, J. & Moghimi, S. M. Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol. Immunol. 46, 225–232 (2008).10.1016/j.molimm.2008.08.276 ↗
16. Dobrovolskaia, M. A. & McNeil, S. E. Immunological properties of engineered nanomaterials. Nature Nanotech. 2, 469–478 (2007).10.1038/nnano.2007.223 ↗
17. Yang, J. et al. Development of aliphatic biodegradable photoluminescent polymers. Proc. Natl Acad. Sci. USA 106, 10086–10091 (2009).10.1073/pnas.0900004106 ↗
18. Barstow, L. & Small, R. E. Liver function assessment by drug metabolism. Pharmacotherapy 10, 280–288 (1990).10.1002/j.1875-9114.1990.tb02584.x ↗
19. McAfee, J. G. et al. Technetium-99 m DADS complexes as renal function and imaging agents: II. Biological comparison with iodine-131 hippuran. J. Nucl. Med. 26, 375–384 (1985).
20. Cai, W. et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett. 6, 669–676 (2006).10.1021/nl052405t ↗
21. Smith, A. M., Duan, H., Mohs, A. M. & Nie, S. Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv. Drug Deliv. Rev. 60, 1226–1240 (2008).10.1016/j.addr.2008.03.015 ↗
22. Chen, K., Li, Z. B., Wang, H., Cai, W. & Chen, X. Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur. J. Nucl. Med. Mol. Imaging 35, 2235–2244 (2008).10.1007/s00259-008-0860-8 ↗
23. Bentolila, L. A., Ebenstein, Y. & Weiss, S. Quantum dots for in vivo small-animal imaging. J. Nucl. Med. 50, 493–496 (2009).10.2967/jnumed.108.053561 ↗
24. Matsumura, Y., Oda, T. & Maeda, H. General mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeutics. Gan To Kagaku Ryoho 14, 821–829 (1987).
25. Humblet, V. et al. High-affinity near-infrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol. Imaging 4, 448–462 (2005).10.2310/7290.2005.05163 ↗
26. Chen, X., Park, R., Shahinian, A. H., Bading, J. R. & Conti, P. S. Pharmacokinetics and tumor retention of 125I-labeled RGD peptide are improved by PEGylation. Nucl. Med. Biol. 31, 11–19 (2004).10.1016/j.nucmedbio.2003.07.003 ↗
27. Liu, W. et al. Compact cysteine-coated CdSe(ZnCdS) quantum dots for in vivo applications. J. Am. Chem. Soc. 129, 14530–14531 (2007).10.1021/ja073790m ↗
28. Davis, M. E., Chen, Z. G. & Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Rev. Drug Discov. 7, 771–782 (2008).10.1038/nrd2614 ↗
29. Choi, H. S. et al. Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett. 9, 2354–2359 (2009).10.1021/nl900872r ↗
30. Tanaka, E., Choi, H. S., Fujii, H., Bawendi, M. G. & Frangioni, J. V. Image-guided oncologic surgery using invisible light: completed pre-clinical development for sentinel lymph node mapping. Ann. Surg. Oncol. 13, 1671–1681 (2006).10.1245/s10434-006-9194-6 ↗